Abstract
A new series of pyridine and pyrimidine derivatives is designed and synthesized as potential antitumor molecules. The tested compounds show promising in vitro cytotoxic activity against HL-60 cell line as eight compounds: 4, 6, 11, 13, 14, 15, 18 and 21 exhibit potent cytotoxic activity in sub-micromolar concentration higher than the combretastatin A4 (CA-4). Compound 21 shows a cytotoxic activity 5-fold more potent than CA-4 on HL-60 cells. DNA-Flow cytometry cell cycle analysis and annexin-V assay on HL-60 cells show that compounds 4, 18 and 21 exhibit potent cell growth inhibition, cell cycle arrest at G2/M phase and proapoptotic inducing activities. The percentage inhibition assay of β-tubulin polymerization on HL-60 cells shows that the antitumor activity of the tested compounds appears to correlate well with its ability to inhibit β-tubulin polymerization. In addition, enzyme-linked immunosorbene assay (ELlSA) measurement for compound 21 shows apoptotic inducing activities through significant up regulation of p53, Bax/Bcl-2 ratio and caspase-3 proteins parallel to down regulation of the level of survivin proteins.
Author supplied keywords
Cite
CITATION STYLE
Elhameid, M. K. A., Ryad, N., My, A. S., Mohammed, M. R., Ismail, M. M., & El Meligie, S. (2018). Design, synthesis and screening of 4,6-diaryl pyridine and pyrimidine derivatives as potential cytotoxic molecules. Chemical and Pharmaceutical Bulletin, 66(10), 939–952. https://doi.org/10.1248/cpb.c18-00269
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.